Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1346–1350. doi: 10.1038/bjc.1993.249

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.

C Haworth 1, S M O'Reilly 1, E Chu 1, G J Rustin 1, M Feldmann 1
PMCID: PMC1968527  PMID: 8512819

Abstract

Twelve patients undergoing IL-2 and flavone acetic acid (FAA) combination immunotherapy for advanced melanoma were studied throughout treatment for the induction of measurable levels of bioactive TNF, GM-CSF and IL-6 in their serum. This was to assess the extent of secondary cytokine induction in these patients and the possible role of such cytokines in both the toxic and therapeutic responses. The nature of the treatment schedule enabled these cytokines to be measured in response to FAA alone, FAA/IL-2 and FAA alone following IL-2/FAA activation of target cells. A small rise in the serum levels of these cytokines was seen on the initial course of FAA/IL-2 but this was minor compared to the marked elevation in levels 2-8 h following the initiation of the third course of FAA given with or without IL-2 and at a time point which coincided with maximum toxicity in those patients who experienced it. These results show that FAA alone can induce cytokine release from primed target cells. This may be associated with the therapeutic effect and/or toxicity of the agent.

Full text

PDF
1346

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Alegre M. L., Gastaldello K., Abramowicz D., Kinnaert P., Vereerstraeten P., De Pauw L., Vandenabeele P., Moser M., Leo O., Goldman M. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation. 1991 Oct;52(4):674–679. doi: 10.1097/00007890-199110000-00018. [DOI] [PubMed] [Google Scholar]
  3. Ascensao J. L., Liu S. J., Caro J., Podack E., Mittelman A., Zanjani E. D., Zhao Y. L. Erythropoiesis in cancer patients undergoing immunotherapy. Adv Exp Med Biol. 1989;271:197–204. doi: 10.1007/978-1-4613-0623-8_20. [DOI] [PubMed] [Google Scholar]
  4. Avanzi G. C., Lista P., Giovinazzo B., Miniero R., Saglio G., Benetton G., Coda R., Cattoretti G., Pegoraro L. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol. 1988 Jul;69(3):359–366. doi: 10.1111/j.1365-2141.1988.tb02374.x. [DOI] [PubMed] [Google Scholar]
  5. Bibby M. C. Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment? Br J Cancer. 1991 Jan;63(1):3–5. doi: 10.1038/bjc.1991.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  7. Cummings J., Smyth J. F. Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother Pharmacol. 1989;24(5):269–272. doi: 10.1007/BF00304756. [DOI] [PubMed] [Google Scholar]
  8. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  9. Ferran C., Dy M., Sheehan K., Schreiber R., Grau G., Bluestone J., Bach J. F., Chatenoud L. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol. 1991 Oct;21(10):2349–2353. doi: 10.1002/eji.1830211009. [DOI] [PubMed] [Google Scholar]
  10. Ferro T. J., Johnson A., Everitt J., Malik A. B. IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes. J Immunol. 1989 Mar 15;142(6):1916–1921. [PubMed] [Google Scholar]
  11. Fraker D. L., Langstein H. N., Norton J. A. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med. 1989 Sep 1;170(3):1015–1020. doi: 10.1084/jem.170.3.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grau G. E., Fajardo L. F., Piguet P. F., Allet B., Lambert P. H., Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science. 1987 Sep 4;237(4819):1210–1212. doi: 10.1126/science.3306918. [DOI] [PubMed] [Google Scholar]
  13. Harms B. A., Pahl A. C., Pohlman T. H., Conhaim R. L., Starling J. R., Storm F. K. Effects of interleukin-2 on pulmonary and systemic transvascular fluid filtration. Surgery. 1989 Aug;106(2):339–346. [PubMed] [Google Scholar]
  14. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983 Apr 1;32(7):1141–1148. doi: 10.1016/0006-2952(83)90262-9. [DOI] [PubMed] [Google Scholar]
  15. Haworth C., Brennan F. M., Chantry D., Turner M., Maini R. N., Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 1991 Oct;21(10):2575–2579. doi: 10.1002/eji.1830211039. [DOI] [PubMed] [Google Scholar]
  16. Kolb H., Kolb-Bachofen V. Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today. 1992 May;13(5):157–160. doi: 10.1016/0167-5699(92)90118-Q. [DOI] [PubMed] [Google Scholar]
  17. Lieschke G. J., Cebon J., Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1989 Dec;74(8):2634–2643. [PubMed] [Google Scholar]
  18. Mahadevan V., Malik S. T., Meager A., Fiers W., Lewis G. P., Hart I. R. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res. 1990 Sep 1;50(17):5537–5542. [PubMed] [Google Scholar]
  19. Mier J. W., Vachino G., van der Meer J. W., Numerof R. P., Adams S., Cannon J. G., Bernheim H. A., Atkins M. B., Parkinson D. R., Dinarello C. A. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. 1988 Nov;8(6):426–436. doi: 10.1007/BF00916947. [DOI] [PubMed] [Google Scholar]
  20. Nakamura Y., Ozaki T., Yanagawa H., Yasuoka S., Ogura T. Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy. Am J Respir Cell Mol Biol. 1990 Oct;3(4):291–300. doi: 10.1165/ajrcmb/3.4.291. [DOI] [PubMed] [Google Scholar]
  21. O'Reilly S. M., Rustin G. J., Farmer K., Burke M., Hill S., Denekamp J. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. Br J Cancer. 1993 Jun;67(6):1342–1345. doi: 10.1038/bjc.1993.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pawelec G., Schwuléra U., Lenz H., Owsianowski M., Bühring H. J., Schlag H., Schneider E., Schaudt K., Ehninger G. Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2. Mol Biother. 1990 Mar;2(1):44–49. [PubMed] [Google Scholar]
  23. Pratesi G., Rodolfo M., Rovetta G., Parmiani G. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer. 1990;26(10):1079–1083. doi: 10.1016/0277-5379(90)90056-y. [DOI] [PubMed] [Google Scholar]
  24. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  25. Sone S., Nakanishi M., Ohmoto Y., Yanagawa H., Ogura T. Macrophage colony-stimulating factor activity in malignant pleural effusions. Its augmentation by intrapleural interleukin-2 infusions. Chest. 1991 Feb;99(2):377–381. doi: 10.1378/chest.99.2.377. [DOI] [PubMed] [Google Scholar]
  26. Thomsen L. L., Baguley B. C., Rustin G. J., O'Reilly S. M. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. Br J Cancer. 1992 Oct;66(4):723–727. doi: 10.1038/bjc.1992.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  28. Tritarelli E., Rocca E., Testa U., Boccoli G., Camagna A., Calabresi F., Peschle C. Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level. Blood. 1991 Feb 15;77(4):741–749. [PubMed] [Google Scholar]
  29. Urba W. J., Longo D. L., Lombardo F. A., Weiss R. B. Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J Natl Cancer Inst. 1988 Jun 1;80(7):521–525. doi: 10.1093/jnci/80.7.521. [DOI] [PubMed] [Google Scholar]
  30. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Waage A., Halstensen A., Shalaby R., Brandtzaeg P., Kierulf P., Espevik T. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med. 1989 Dec 1;170(6):1859–1867. doi: 10.1084/jem.170.6.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wiltrout R. H., Boyd M. R., Back T. C., Salup R. R., Arthur J. A., Hornung R. L. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol. 1988 May 1;140(9):3261–3265. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES